I-Lumen Scientific has received an Investigational Device Exemption from the FDA for its i-SIGHT2 pivotal study, which will assess a non-invasive bioelectric stimulation therapy for patients with intermediate to advanced dry age-related macular degeneration (AMD). This significant development allows for U.S. enrollment in a multinational trial that is already underway in the UK, Australia, and New Zealand, with plans to include 120 participants across all sites. The study has already marked its first operational milestone, having randomized and treated its initial participant in the UK.

This trial is particularly noteworthy as it explores a novel therapeutic approach to a condition that significantly impacts the aging population’s vision and quality of life. The i-Lumen AMD System employs microcurrent stimulation aimed at enhancing retinal pigment epithelium function and supporting photoreceptor health. If successful, the study could demonstrate improvements in visual acuity for patients suffering from vision loss due to AMD, potentially paving the way for regulatory approvals and subsequent commercialization in both the U.S. and international markets.

For professionals in the longevity and healthspan research fields, the implications of this study extend beyond AMD treatment. The trial underscores a growing interest in non-invasive therapies that leverage bioelectric stimulation to promote cellular health and function. Should the results be favorable, it may inspire further research into similar approaches for other age-related conditions, highlighting a promising direction in the development of longevity therapeutics.

Source: longevity.technology